Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.

Clark RE, Polydoros F, Apperley JF, Milojkovic D, Rothwell K, Pocock C, Byrne J, de Lavallade H, Osborne W, Robinson L, O'Brien SG, Read L, Foroni L, Copland M.

Lancet Haematol. 2019 Jul;6(7):e375-e383. doi: 10.1016/S2352-3026(19)30094-8. Epub 2019 Jun 12.

PMID:
31201085
2.

Is There a Role for Dose Modification of TKI Therapy in CML?

Copland M.

Curr Hematol Malig Rep. 2019 Aug;14(4):337-345. doi: 10.1007/s11899-019-00524-w. Review.

3.

Buttonhole versus Stepladder Cannulation for Home Hemodialysis: A Multicenter, Randomized, Pilot Trial.

Huang SS, MacRae J, Ross D, Imtiaz R, Hollingsworth B, Nesrallah GE, Copland MA, McFarlane PA, Chan CT, Zimmerman D.

Clin J Am Soc Nephrol. 2019 Mar 7;14(3):403-410. doi: 10.2215/CJN.08310718. Epub 2019 Jan 18.

PMID:
30659057
4.

Type B lactic acidosis from fluorouracil in fluorouracil, oxaliplatin and leucovorin treatment for carcinoma of the colon in a hemodialysis patient.

Yeung EK, Copland MA, Gill S.

Clin Kidney J. 2018 Dec;11(6):786-787. doi: 10.1093/ckj/sfy012. Epub 2018 Mar 12.

5.

Technique Failure in a Multicenter Canadian Home Hemodialysis Cohort.

Pauly RP, Rosychuk RJ, Usman I, Reintjes F, Muneer M, Chan CT, Copland M, Lindsay R, MacRae J, Nesrallah G, Pierratos A, Zimmerman DL, Komenda P.

Am J Kidney Dis. 2019 Feb;73(2):230-239. doi: 10.1053/j.ajkd.2018.08.016. Epub 2018 Nov 2.

PMID:
30392981
6.

Chronic myeloid leukaemia cells require the bone morphogenic protein pathway for cell cycle progression and self-renewal.

Toofan P, Busch C, Morrison H, O'Brien S, Jørgensen H, Copland M, Wheadon H.

Cell Death Dis. 2018 Sep 11;9(9):927. doi: 10.1038/s41419-018-0905-2.

7.

Consensus on BCR-ABL1 reporting in chronic myeloid leukaemia in the UK.

Cross NCP, White HE, Evans PAS, Hancock J, Copland M, Milojkovic D, Mason J, Craine S, Mead AJ.

Br J Haematol. 2018 Sep;182(6):777-788. doi: 10.1111/bjh.15542. Epub 2018 Aug 20. Review.

8.

Exploring Stem Cell Heterogeneity in Chronic Myeloid Leukemia.

Munje C, Copland M.

Trends Cancer. 2018 Mar;4(3):167-169. doi: 10.1016/j.trecan.2017.12.001. Epub 2017 Dec 21.

PMID:
29506666
9.

Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia.

Zhang B, Nguyen LXT, Li L, Zhao D, Kumar B, Wu H, Lin A, Pellicano F, Hopcroft L, Su YL, Copland M, Holyoake TL, Kuo CJ, Bhatia R, Snyder DS, Ali H, Stein AS, Brewer C, Wang H, McDonald T, Swiderski P, Troadec E, Chen CC, Dorrance A, Pullarkat V, Yuan YC, Perrotti D, Carlesso N, Forman SJ, Kortylewski M, Kuo YH, Marcucci G.

Nat Med. 2018 May;24(4):450-462. doi: 10.1038/nm.4499. Epub 2018 Mar 5.

10.

Prevalence-Based Targets Underestimate Home Dialysis Program Activity and Requirements for Growth.

Bevilacqua MU, Er L, Copland MA, Singh RS, Jamal A, Dunne ÓM, Brumby C, Levin A.

Perit Dial Int. 2018 May-Jun;38(3):200-205. doi: 10.3747/pdi.2017.00171. Epub 2018 Feb 7.

PMID:
29437142
11.

Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia.

Kinstrie R, Karamitros D, Goardon N, Morrison H, Hamblin M, Robinson L, Clark RE, Copland M, Vyas P.

Blood Adv. 2016 Dec 14;1(3):160-169. doi: 10.1182/bloodadvances.2016000810. eCollection 2016 Dec 27.

12.

Implementing the EffTox dose-finding design in the Matchpoint trial.

Brock K, Billingham L, Copland M, Siddique S, Sirovica M, Yap C.

BMC Med Res Methodol. 2017 Jul 20;17(1):112. doi: 10.1186/s12874-017-0381-x.

13.

De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial.

Clark RE, Polydoros F, Apperley JF, Milojkovic D, Pocock C, Smith G, Byrne JL, de Lavallade H, O'Brien SG, Coffey T, Foroni L, Copland M.

Lancet Haematol. 2017 Jul;4(7):e310-e316. doi: 10.1016/S2352-3026(17)30066-2. Epub 2017 May 26.

14.

Approaches for targeting self-renewal pathways in cancer stem cells: implications for hematological treatments.

Horne GA, Copland M.

Expert Opin Drug Discov. 2017 May;12(5):465-474. doi: 10.1080/17460441.2017.1303477. Epub 2017 Mar 14. Review.

PMID:
28277836
15.

Evaluation of a 12-Month Pilot of Long-Term and Temporary Assisted Peritoneal Dialysis.

Bevilacqua MU, Turnbull L, Saunders S, Er L, Chiu H, Hill P, Singh RS, Levin A, Copland MA, Jamal A, Brumby C, Dunne O, Taylor PA.

Perit Dial Int. 2017 May-Jun;37(3):307-313. doi: 10.3747/pdi.2016.00201. Epub 2016 Dec 1.

PMID:
27935536
16.

Intensive Hemodialysis and Potential Risks With Increasing Treatment.

Kraus MA, Kansal S, Copland M, Komenda P, Weinhandl ED, Bakris GL, Chan CT, Fluck RJ, Burkart JM.

Am J Kidney Dis. 2016 Nov;68(5S1):S51-S58. doi: 10.1053/j.ajkd.2016.05.020. Review.

PMID:
27772644
17.

Intensive Hemodialysis and Health-Related Quality of Life.

Kraus MA, Fluck RJ, Weinhandl ED, Kansal S, Copland M, Komenda P, Finkelstein FO.

Am J Kidney Dis. 2016 Nov;68(5S1):S33-S42. doi: 10.1053/j.ajkd.2016.05.023. Review.

PMID:
27772641
18.

Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.

Copland M, Komenda P, Weinhandl ED, McCullough PA, Morfin JA.

Am J Kidney Dis. 2016 Nov;68(5S1):S24-S32. doi: 10.1053/j.ajkd.2016.05.024. Review.

PMID:
27772640
19.

What are the challenges in 2016 regarding resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and cancer?

Lewis M, Copland M, Soverini S, Sadovnik I, Bedel A, Prost S, Italiano A, Mahon FX.

Hematol Oncol. 2017 Dec;35(4):420-423. doi: 10.1002/hon.2329. Epub 2016 Jul 19.

PMID:
27435333
20.

Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells.

Abraham SA, Hopcroft LE, Carrick E, Drotar ME, Dunn K, Williamson AJ, Korfi K, Baquero P, Park LE, Scott MT, Pellicano F, Pierce A, Copland M, Nourse C, Grimmond SM, Vetrie D, Whetton AD, Holyoake TL.

Nature. 2016 Jun 16;534(7607):341-6. doi: 10.1038/nature18288. Epub 2016 Jun 8.

21.

Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia.

Irvine DA, Zhang B, Kinstrie R, Tarafdar A, Morrison H, Campbell VL, Moka HA, Ho Y, Nixon C, Manley PW, Wheadon H, Goodlad JR, Holyoake TL, Bhatia R, Copland M.

Sci Rep. 2016 May 9;6:25476. doi: 10.1038/srep25476.

22.

Combined Population Dynamics and Entropy Modelling Supports Patient Stratification in Chronic Myeloid Leukemia.

Brehme M, Koschmieder S, Montazeri M, Copland M, Oehler VG, Radich JP, Brümmendorf TH, Schuppert A.

Sci Rep. 2016 Apr 6;6:24057. doi: 10.1038/srep24057.

23.

Mtss1 is a critical epigenetically regulated tumor suppressor in CML.

Schemionek M, Herrmann O, Reher MM, Chatain N, Schubert C, Costa IG, Hänzelmann S, Gusmao EG, Kintsler S, Braunschweig T, Hamilton A, Helgason GV, Copland M, Schwab A, Müller-Tidow C, Li S, Holyoake TL, Brümmendorf TH, Koschmieder S.

Leukemia. 2016 Apr;30(4):823-32. doi: 10.1038/leu.2015.329. Epub 2015 Dec 1.

PMID:
26621336
24.

Novel drug therapies in myeloid leukemia.

Horne GA, Kinstrie R, Copland M.

Pharm Pat Anal. 2015;4(3):187-205. doi: 10.4155/ppa.15.3. Review.

25.

Hedgehog signaling in cancer stem cells: a focus on hematological cancers.

Campbell V, Copland M.

Stem Cells Cloning. 2015 Jan 16;8:27-38. doi: 10.2147/SCCAA.S58613. eCollection 2015. Review.

26.

DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML.

Lund K, Cole JJ, VanderKraats ND, McBryan T, Pchelintsev NA, Clark W, Copland M, Edwards JR, Adams PD.

Genome Biol. 2014 Aug 30;15(8):406. doi: 10.1186/s13059-014-0406-2.

27.

The role of the bone morphogenetic proteins in leukaemic stem cell persistence.

Toofan P, Irvine D, Hopcroft L, Copland M, Wheadon H.

Biochem Soc Trans. 2014 Aug;42(4):809-15. doi: 10.1042/BST20140037. Review.

PMID:
25109962
28.

The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors.

Pellicano F, Scott MT, Helgason GV, Hopcroft LE, Allan EK, Aspinall-O'Dea M, Copland M, Pierce A, Huntly BJ, Whetton AD, Holyoake TL.

Stem Cells. 2014 Sep;32(9):2324-37. doi: 10.1002/stem.1748.

29.

Effectiveness of deep cleaning followed by hydrogen peroxide decontamination during high Clostridium difficile infection incidence.

Best EL, Parnell P, Thirkell G, Verity P, Copland M, Else P, Denton M, Hobson RP, Wilcox MH.

J Hosp Infect. 2014 May;87(1):25-33. doi: 10.1016/j.jhin.2014.02.005. Epub 2014 Mar 12.

PMID:
24746230
30.

A 'telomere-associated secretory phenotype' cooperates with BCR-ABL to drive malignant proliferation of leukemic cells.

Braig M, Pällmann N, Preukschas M, Steinemann D, Hofmann W, Gompf A, Streichert T, Braunschweig T, Copland M, Rudolph KL, Bokemeyer C, Koschmieder S, Schuppert A, Balabanov S, Brümmendorf TH.

Leukemia. 2014 Oct;28(10):2028-39. doi: 10.1038/leu.2014.95. Epub 2014 Mar 7.

PMID:
24603533
31.

Progress in dialysis practice: an introduction.

MacRae JM, Copland M, Kiaii M.

Semin Dial. 2014 Mar;27(2):85-6. doi: 10.1111/sdi.12202. No abstract available.

PMID:
24588801
32.

In a 12-allele analysis HLA-DPB1 matching is associated with improved OS in leukaemic and myelodysplastic patients receiving myeloablative T-cell-depleted PBSCT from unrelated donors.

Burt C, Parker A, McQuaker G, Copland M, Brierley C, Little AM, Clark A.

Bone Marrow Transplant. 2014 May;49(5):657-63. doi: 10.1038/bmt.2014.8. Epub 2014 Feb 17.

PMID:
24535129
33.

Rationale for a home dialysis virtual ward: design and implementation.

Schachter ME, Bargman JM, Copland M, Hladunewich M, Tennankore KK, Levin A, Oliver M, Pauly RP, Perl J, Zimmerman D, Chan CT.

BMC Nephrol. 2014 Feb 14;15:33. doi: 10.1186/1471-2369-15-33.

34.

Programmatic variation in home hemodialysis in Canada: results from a nationwide survey of practice patterns.

Pauly RP, Komenda P, Chan CT, Copland M, Gangji A, Hirsch D, Lindsay R, MacKinnon M, MacRae JM, McFarlane P, Nesrallah G, Pierratos A, Plaisance M, Reintjes F, Rioux JP, Shik J, Steele A, Stryker R, Wu G, Zimmerman DL.

Can J Kidney Health Dis. 2014 Jun 10;1:11. doi: 10.1186/2054-3581-1-11. eCollection 2014.

35.

Allogeneic stem cell transplantation for chronic myeloid leukaemia is safe and effective in high risk patients following second generation tyrosine kinase inhibitors: A single centre's experience.

Latif AL, McQuaker G, Parker A, Clark A, Copland M.

Leuk Res Rep. 2013 Jul 3;2(2):47-50. doi: 10.1016/j.lrr.2013.05.001. eCollection 2013.

36.

EZH2 in normal and malignant hematopoiesis.

Lund K, Adams PD, Copland M.

Leukemia. 2014 Jan;28(1):44-9. doi: 10.1038/leu.2013.288. Epub 2013 Oct 7. Review.

PMID:
24097338
37.

Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation.

Gallipoli P, Pellicano F, Morrison H, Laidlaw K, Allan EK, Bhatia R, Copland M, Jørgensen HG, Holyoake TL.

Blood. 2013 Nov 7;122(19):3335-9. doi: 10.1182/blood-2013-02-485607. Epub 2013 Sep 16.

38.

Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile.

Cramer-Morales K, Nieborowska-Skorska M, Scheibner K, Padget M, Irvine DA, Sliwinski T, Haas K, Lee J, Geng H, Roy D, Slupianek A, Rassool FV, Wasik MA, Childers W, Copland M, Müschen M, Civin CI, Skorski T.

Blood. 2013 Aug 15;122(7):1293-304. doi: 10.1182/blood-2013-05-501072. Epub 2013 Jul 8.

39.

Vascular access for intensive maintenance hemodialysis: a systematic review for a Canadian Society of Nephrology clinical practice guideline.

Mustafa RA, Zimmerman D, Rioux JP, Suri RS, Gangji A, Steele A, MacRae J, Pauly RP, Perkins DN, Chan CT, Copland M, Komenda P, McFarlane PA, Lindsay R, Pierratos A, Nesrallah GE.

Am J Kidney Dis. 2013 Jul;62(1):112-31. doi: 10.1053/j.ajkd.2013.03.028. Review.

PMID:
23773840
40.

Targeting self-renewal pathways in myeloid malignancies.

Sands WA, Copland M, Wheadon H.

Cell Commun Signal. 2013 May 15;11(1):33. doi: 10.1186/1478-811X-11-33.

41.

Dialysate calcium concentration and mineral metabolism in long and long-frequent hemodialysis: a systematic review and meta-analysis for a Canadian Society of Nephrology clinical practice guideline.

Zimmerman DL, Nesrallah GE, Chan CT, Copland M, Komenda P, McFarlane PA, Gangji A, Lindsay R, MacRae J, Pauly RP, Perkins DN, Pierratos A, Rioux JP, Steele A, Suri RS, Mustafa RA.

Am J Kidney Dis. 2013 Jul;62(1):97-111. doi: 10.1053/j.ajkd.2013.02.357. Epub 2013 Apr 13. Review.

PMID:
23591289
42.

Canadian Society of Nephrology guidelines for the management of patients with ESRD treated with intensive hemodialysis.

Nesrallah GE, Mustafa RA, MacRae J, Pauly RP, Perkins DN, Gangji A, Rioux JP, Steele A, Suri RS, Chan CT, Copland M, Komenda P, McFarlane PA, Pierratos A, Lindsay R, Zimmerman DL.

Am J Kidney Dis. 2013 Jul;62(1):187-98. doi: 10.1053/j.ajkd.2013.02.351. Epub 2013 Apr 6. Review.

PMID:
23566638
43.

Heterogeneity of neoplastic stem cells: theoretical, functional, and clinical implications.

Valent P, Bonnet D, Wöhrer S, Andreeff M, Copland M, Chomienne C, Eaves C.

Cancer Res. 2013 Feb 1;73(3):1037-45. doi: 10.1158/0008-5472.CAN-12-3678. Epub 2013 Jan 23. Review.

44.

Targeting chronic myeloid leukemia stem cells.

Kinstrie R, Copland M.

Curr Hematol Malig Rep. 2013 Mar;8(1):14-21. doi: 10.1007/s11899-012-0148-8. Review.

PMID:
23264204
45.

Quantitative proteomics analysis of BMS-214662 effects on CD34 positive cells from chronic myeloid leukaemia patients.

Balabanov S, Evans CA, Abraham SA, Pellicano F, Copland M, Walker MJ, Whetton AD, Holyoake TL.

Proteomics. 2013 Jan;13(1):153-68. doi: 10.1002/pmic.201200022.

PMID:
23184491
46.

Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemia.

Eyre T, Schwab CJ, Kinstrie R, McGuire AK, Strefford J, Peniket A, Mead A, Littlewood T, Holyoake TL, Copland M, Moorman AV, Harrison CJ, Vyas P.

Blood. 2012 Nov 22;120(22):4441-3. doi: 10.1182/blood-2012-09-456517. No abstract available.

47.

Cancer stem cell definitions and terminology: the devil is in the details.

Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, Chomienne C, Ishikawa F, Schuringa JJ, Stassi G, Huntly B, Herrmann H, Soulier J, Roesch A, Schuurhuis GJ, Wöhrer S, Arock M, Zuber J, Cerny-Reiterer S, Johnsen HE, Andreeff M, Eaves C.

Nat Rev Cancer. 2012 Nov;12(11):767-75. doi: 10.1038/nrc3368. Epub 2012 Oct 11. Review.

PMID:
23051844
48.

Optimizing AVF creation prior to dialysis start: the role of predialysis renal replacement therapy choices.

Hanko J, Romann A, Taylor P, Copland M, Beaulieu M.

Nephrol Dial Transplant. 2012 Nov;27(11):4205-10. doi: 10.1093/ndt/gfs378. Epub 2012 Sep 7.

PMID:
22962410
49.

Chronic myeloid leukemia stem cells display alterations in expression of genes involved in oxidative phosphorylation.

Flis K, Irvine D, Copland M, Bhatia R, Skorski T.

Leuk Lymphoma. 2012 Dec;53(12):2474-8. doi: 10.3109/10428194.2012.696313. Epub 2012 Jun 18.

PMID:
22616753
50.

How I manage priapism in chronic myeloid leukaemia patients.

Rodgers R, Latif Z, Copland M.

Br J Haematol. 2012 Jul;158(2):155-164. doi: 10.1111/j.1365-2141.2012.09151.x. Epub 2012 May 10. Review.

PMID:
22571386

Supplemental Content

Loading ...
Support Center